49388 Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel; Career Development in 

Environmental Research. 

Date: November 2, 2017. 

Time: 8:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIEHS/National Institutes of Health 

Keystone Building, 530 Davis Drive, Research 

Triangle Park, NC 27709 (Virtual Meeting). 

Contact Person: Laura A. Thomas, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research and 

Training, National Institute of Environmental 

Health Sciences, Research Triangle Park, NC 

27709, 919–541–2824, laura.thomas@

nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: October 20, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–23180 Filed 10–24–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

patent applications listed below may be 

obtained by emailing the indicated 

licensing contact at the National Heart, 

Lung, and Blood, Office of Technology 

Transfer and Development Office of 

Technology Transfer, 31 Center Drive 

Room 4A29, MSC2479, Bethesda, MD 

20892–2479; telephone: 301–402–5579. 

A signed Confidential Disclosure 

Agreement may be required to receive 

copies of the patent applications. 

SUPPLEMENTARY INFORMATION: This 

notice is in accordance with 35 U.S.C. 

209 and 37 CFR part 404 to achieve 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. A description of the 

technology follows. 

Segmented Metallic Guidewires 

Description of Technology: The 

invention pertains to segmented 

metallic guidewires that are suitable for 

MRI catheterization. Guidewires contain 

plurality of short conductive metallic 

segments that are individually short 

enough to not resonate during MR 

imaging. The conductive segments are 

electrically insulated from each other 

and mechanically coupled together endto-end via connectors, such as stiffness 

matched connectors, to provide a 

sufficiently long, strong, and flexible 

guidewire for catheterization that is 

non-resonant during MRI. 

Potential Commercial Applications: 

Endovascular interventions. 

Inventors: Robert Lederman, Ozgur 

Kocaturk, Burcu Basar (NHLBI). 

Intellectual Property: HHS Reference 

No. E–253–2014/0, U.S. Provisional 

Patent Application 61/066,167 filed 

October 20, 2014, International Patent 

Application PCT/US2015/056266 filed 

October 19, 2015, European Patent 

Application 15787824.0 October 19, 

2015 and U.S. Patent Application 15/ 

514,744 filed March 27, 2017. 

Licensing Contact: Michael 

Shmilovich, Esq, CLP; 301–435–5019; 

shmilovm@nih.gov. 

Dated: October 18, 2017. 

Michael Shmilovich, 

Senior Licensing and Patenting Manager, 

National Heart, Lung, and Blood Institute, 

Office of Technology Transfer and 

Development. 

[FR Doc. 2017–23178 Filed 10–24–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Library of 

Medicine Special Emphasis Panel; R01/F31/ 

K01/K99 Conflicts. 

Date: December 1, 2017. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Library of Medicine/Center 

for Scientific Review, 6701 Rockledge Drive, 

Room 3042, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Zoe E. Huang, MD, 

Scientific Review Officer, Division of 

Extramural Programs, National Library of 

Medicine, NIH, 6705 Rockledge Drive, Suite 

301, Bethesda, MD 20892–7968, 301–594– 

4937, huangz@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.879, Medical Library 

Assistance, National Institutes of Health, 

HHS) 

Dated: October 19, 2017. 

Michelle Trout, 

Program Analyst, Office of the Federal 

Advisory Committee Policy. 

[FR Doc. 2017–23129 Filed 10–24–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; MultiVerDate Sep<11>2014 22:06 Oct 24, 2017 Jkt 244001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 E:\FR\FM\25OCN1.SGM 25OCN1

sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices 49389 

Site Studies for System-Level 

Implementation of Substance Use Prevention 

and Treatment Services (R01; R34). 

Date: November 7, 2017. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, NIH, DHHS, 6001 

Executive Blvd., Room 4238, MSC 9550, 

Bethesda, MD 20892–9550, 301–827–5819, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Limited 

Competition—Cohort Studies of HIV/AIDS 

and Substance Abuse (U01). 

Date: November 7, 2017. 

Time: 2:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Hiromi Ono, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Boulevard, 

Room 4238, MSC 9550, Bethesda, MD 20892, 

301–827–5820, hiromi.ono@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Advancing Exceptional Research on HIV/ 

AIDS and Substance Abuse (R01). 

Date: November 10, 2017. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Hiromi Ono, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Boulevard, 

Room 4238, MSC 9550, Bethesda, MD 20892, 

301–827–5820, hiromi.ono@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Wearable to Track Recovery and Relapse 

Factors for People w/Addiction (R43, R44). 

Date: November 21, 2017. 

Time: 1:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Julia Berzhanskaya, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, Room 4234, MSC 9550, Bethesda, 

MD 20892, 301–827–5840, 

julia.berzhanskaya@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Research Education Program for Clinical 

Researchers and Clinicians (R25). 

Date: December 4, 2017. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, NIH, DHHS, 6001 

Executive Blvd., Room 4238, MSC 9550, 

Bethesda, MD 20892–9550, 301–827–5819, 

gm145a@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Nasal 

Delivery of CNS Therapeutics (R41, R42, R43, 

R44). 

Date: December 5, 2017. 

Time: 1:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Julia Berzhanskaya, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, Room 4234, MSC 9550, Bethesda, 

MD 20892, 301–827–5840, 

julia.berzhanskaya@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Conference Grant Review (R13). 

Date: December 6, 2017. 

Time: 1:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Shang-Yi Anne Tsai, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, Room 4228, MSC 9550, Bethesda, 

MD 20892, 301–827–5842, shangyi.tsai@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: October 19, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–23128 Filed 10–24–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Amy Petrik, 240–627–3721; 

amy.petrik@nih.gov. Licensing 

information and copies of the U.S. 

patent application listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD, 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Neutralizing Antibodies to Influenza 

HA and Their Use and Identification 

Description of Technology: The 

effectiveness of current influenza 

vaccines varies by strain and season, in 

part because influenza viruses 

continuously evolve to evade human 

immune responses. While the majority 

of seasonal influenza infections cause 

relatively mild symptoms, each year 

influenza virus infections result in over 

500,000 hospitalizations in the United 

States and Europe. Current standard of 

care for individuals hospitalized with 

uncomplicated influenza infection is 

administration of neuraminidase 

inhibitors. However, frequent use of 

such antiviral drugs increases the risk 

that the virus will develop drug 

resistance, especially in high-risk 

populations. Thus, alternative strategies 

are required to protect or treat 

vulnerable populations who have been 

hospitalized with severe influenza. 

Using a combination of recombinant 

proteins and sophisticated flow 

cytometry, scientists at NIAID isolated 

families of antibodies capable of 


sradovich on DSK3GMQ082PROD with NOTICES